Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc.

NAUT·NASDAQ

$2.58

-3.7%
HealthcareBiotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

At a Glance

Live Snapshot
Market Cap$327.86M
EPS-0.4700
P/E Ratio-5.49
Earnings Date08/04/2026

naut

Net Debt

Last Annual Value

17.63M

3-Year CAGR

30%

5-Year CAGR

21%

10-Year CAGR

17%

Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Competitors Analysis of Net Debt

NAUT · NASDAQ
CompanyNet Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
17.63M
5.0%N/AN/A 
-89.72M
N/AN/AN/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
-109.41M
N/AN/AN/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
14.35M
N/AN/AN/A
-205.91M
N/AN/AN/A
-34.94M
N/AN/AN/A
-124.82M
N/AN/AN/A
AGEN logo
Agenus Inc.
NASDAQ:AGEN
331.90M
168.9%N/A19.9%
-36.17M
N/AN/AN/A
-65.88M
N/AN/AN/A
-3.12M
N/AN/AN/A
Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Fair Value Envelope

NAUT · NASDAQ

Our analysis suggests that NAUT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.58, this represents a potential HIDDEN relative to our calculated worth for Nautilus Biotechnology, Inc..

Intrinsic Value
Current Price: $2.58